[Recent advances in the treatment of the acute hepatitis C].

Abstract

Acute hepatitis C is characterized by a frequent evolution in chronic form (70-85% of cases). The recent literature evidences that Peg-interferon alpha-2b is efficacy for the treatment of acute hepatitis C (90% of sustained response). Treatment, independently by HCV genotype and baseline viral load, must be prolonged for three months and it must be started into three months by onset.

• Authors: Emilio Palumbo
• Journal: Recenti progressi in medicina (Recenti Prog Med) Vol. 98 Issue 4 Pg. 236-7 (Apr 2007) ISSN: 0034-1193 [Print] Italy
• Vernacular Title: Recenti progressi nel trattamento dell'epatite acuta HCV-correlata.
• PMID: 17547361 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Polyethylene Glycols
• peginterferon alfa-2b

Topics

• Acute Disease
• Antiviral Agents (therapeutic use)
• Hepatitis C (drug therapy)
• Humans
• Interferon alpha-2
• Interferon-alpha (therapeutic use)
• Polyethylene Glycols
• Recombinant Proteins
• Time Factors
• Treatment Outcome